 |
Development
of a minimal set of prescribing quality indicators for diabetes
management on a general practice level |
| |
We showed that a minimal set of prescribing
quality indicators for type 2 diabetes mellitus care should not
just focus on the management of different clinical risk factors
but also reflect different steps of treatment intensification (Pharmacoepidemiology
and Drug Safety) |
| |
|
|
Initial
and subsequent therapy for newly diagnosed type 2 diabetes patients
treated in primary care using data from a vendor-based electronic
health record |
| |
Clinical and demographic characteristics influence
choice and duration of initial oral hypoglycemic treatment as well
as regimen changes (Pharmacoepidemiology and Drug Safety) |
| |
|
|
New
tool to recognise depression in diabetes |
| |
A new e-skill module to enable nurses and GP’s
to spot the signs and manage depression in patients with diabetes
launched at Guy’s Hospital (King’s College London) |
| |
|
|
Feasibility
of prolonged continuous glucose monitoring in toddlers with type
1 diabetes |
| |
More than 40% of very young children were able
to safely use CGM on a near-daily basis after 6 months. CGM demonstrated
frequent hyperglycemic excursions, with a large variability in
glucose readings. Although improvement in glycemic control was
not detected in the group as a whole, parental satisfaction with
CGM was high (Pediatric Diabetes) |
| |
|
|
Evaluation
of a combined blood glucose monitoring and gaming system (Didget®) for motivation in children, adolescents, and young adults with type 1 diabetes |
| |
Most HCPs agreed that the system fulfilled a
need in diabetes management. In conclusion, the Didget® system was precise and clinically accurate in the hands of children, adolescents,
and young adults with type 1 diabetes (Pediatric Diabetes) |
| |
|
|
Poor
achievement of guidelines-recommended targets in type 2 diabetes:
findings from a contemporary prospective cohort study |
| |
Improvements in the attainment of guidelines-recommended
targets in patients with type 2 diabetes followed for a 12-month
period in the primary care setting; however, many individuals still
failed to achieve and especially maintain optimal goals for therapy,
particularly the triple target. Results of the multivariable analysis
reinforce the need to address barriers to improve diabetes care,
particularly in more susceptible groups (International Journal
of Clinical Practice) |
| |
|
|
Impact
of a single one to one education on glycaemic control in patients
with diabetes |
| |
A single episode of one to one diabetic and
dietetic education to subjects with poor diabetic control is effective
in improving short and long term diabetic control upto 1 year with
male patients having a better response (Journal of Diabetes) |
| |
|
|
Diabetes
threatens to 'bankrupt' NHS within a generation |
| |
Treatment will use £16.9bn
of budget as the number of diabetics rises from 3.8m patients to
6.25m by 2035 (Guardian, UK) |
| |
|
|
Vascular
stem cells in diabetic complications: evidence for a role in
the pathogenesis and the therapeutic promise |
| |
In this article, we summarize the vascular changes
that occur in diabetic complications highlighting some of the common
features, the key findings that illustrate an important role of
vascular stem cells (VSCs) in the pathogenesis of chronic diabetic
complications, and provide mechanisms by which these cells can
be used for therapy - provisional PDF (Cardiovascular Diabetology) |
| |
|
|
KATP
channel mutations in infants with permanent diabetes diagnosed
after 6 months of life |
| |
KATP channel mutations are an uncommon cause
of diabetes in infants presenting after 6 months. However, given
the potential clinical benefit from identifying a KATP channel
mutation, we recommend that KATP mutation testing should be routinely
extended to infants diagnosed up to 9 month (Pediatric Diabetes) |
| |
|
|
Markedly
reduced rate of diabetic ketoacidosis at onset of type 1 diabetes
in relatives screened for islet autoantibodies |
| |
Screening for islet autoantibodies in children
likely leads to earlier diabetes diagnosis resulting in less complications
at diagnosis. However, no substantial benefit in the clinical outcome
during the first 5 yr after diagnosis was observed (Pediatric Diabetes) |
| |
|
|
European
Medicines Agency recommends authorisation of novel treatment
for type 2 diabetes |
| |
The European Medicines Agency’s
Committee for Medicinal Products for Human Use (CHMP) has recommended
the granting of a marketing authorisation for Forxiga (dapagliflozin),
a novel treatment for type 2 diabetes mellitus (European Medicines
Agency) |
| |
|
|
Effects
of incretins on blood pressure: A promising therapy for type
2 diabetes mellitus with hypertension |
| |
We conclude that incretins can lower blood pressure
of T2DM patients, independent of weight loss, and will surely improve
the prognosis of these patients (Journal of Diabetes) |
| |
|
|
What's
in a P -value? |
| |
When you read articles looking for important
results between treatment groups or populations of patients, how
do you know what differences between the populations are significant?
Here is where the mystical "p-value" comes into play. I wonder how many of our readers actually know what a p-value
represents? (PRESENT Podiatry) |
| |
|
